|Dr. Lishan Aklog M.D.||Chairman & CEO||686.3k||N/A||1966|
|Mr. Dennis M. McGrath CPA||Pres, CFO & Corp. Sec.||517.7k||N/A||1957|
|Dr. Brian J. deGuzman M.D.||Chief Medical Officer & Exec. VP of Clinical Affairs||427.2k||N/A||1965|
|Mike Havrilla||Director of Investor Relations||N/A||N/A||N/A|
|Mr. Shaun M. O'Neil||Chief Commercial Officer||N/A||N/A||N/A|
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.
PAVmed Inc.’s ISS Governance QualityScore as of June 1, 2021 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 4; Compensation: 10.